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Introduction
Amyotrophic Lateral Sclerosis (ALS) is a degenerative
disease of unknown origin characterized by the pro-
gressive loss of motor neurons of the anterior horns
in the spinal cord, bulb and cortex. Among the several
pathogenetic mechanisms considered in an attempt to
explain motor neuron death in ALS, the hypothesis of
the occurrence of oxidative stress has recently re-
ceived considerable interest. The first suggestion of a
possible role of the involvement of reactive oxygen
species production mechanisms in this disease de-
rives from the observation that mutations in the
copper/zinc superoxide dismutase-1 (SOD-1) gene are
responsible for approximately 20% of familial ALS
(fALS) cases, mainly inherited with an autosomal
dominant trait [4, 19].
A bulk of evidence supports the oxidative stress
hypothesis also in sporadic ALS (sALS). Studies on
post-mortem tissues from sALS patients provided
evidence of accumulation of oxidative damage to
proteins, lipids, or DNA [3, 26]. Biochemical markers
of oxidative stress such as malondialdehyde and
8-hydroxy-2-deoxyguanosine [12, 27, 28] were found
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j Abstract Background The
causes of Amyotrophic Lateral
Sclerosis (ALS) are unknown. A
bulk of evidence supports the
hypothesis that oxidative stress
and mitochondrial dysfunction
can be implicated in ALS patho-
genesis. Methods We assessed, in
cerebrospinal fluid (CSF) and in
plasma of 49 ALS patients and
8 controls, the amount of oxidized
proteins (AOPP, advanced oxida-
tion protein products), the total
antioxidant capacity (FRA, the
ferric reducing ability), and, in
CSF, two oxidation products, the
4-hydroxynonenal and the sum of
nitrites plus nitrates. Results The
FRA was decreased (p = 0.003) in
CSF, and AOPP were increased in
both CSF (p = 0.0039) and plasma
(p = 0.001) of ALS patients. The
content of AOPP was differently
represented in CSF of ALS clinical
subsets, resulting in increase in
the common and pseudopolyneu-
ropathic forms (p < 0.001) and
nearly undetectable in the bulbar
form, as in controls. The sum of
nitrites plus nitrates and 4-hy-
droxynonenal were unchanged in
ALS patients compared with con-
trols. Conclusion Our results,
while confirming the occurrence
of oxidative stress in ALS, indicate
how its effects can be stratified
and therefore implicated differ-
ently in the pathogenesis of dif-
ferent clinical forms of ALS.
j Key words amyotrophic lateral
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normal subjects. Related to that, a number of studies
have suggested a potential role of mitochondrial
dysfunction as responsible for increased production
of reactive oxygen species in ALS. Multiple respira-
tory chain enzyme deficiencies have been reported in
skeletal muscle of ALS patients [30, 33]. Further a
decrease in cytochrome c oxidase activity has also
been observed in motor neurons in patients with sALS
[10].
The aim of the present study has been to further
contribute to the understanding of what extent there
is involvement of oxidative stress in ALS and in its
different clinical forms. To do that we have assessed
some markers of oxidative stress in cerebrospinal




The study included 49 patients, 31 males and 18 females, mean age
62.73 ± SD 10.82-years. ALS diagnosis was made on the basis of the
revised El Escorial criteria [8]. Four cases were affected by fALS,
with G46S SOD1 mutation. Ten patients presented with the bulbar
form of disease, twenty-one the classic form and the remaining
cases progressive muscular atrophy. The control group was rep-
resented by 8 subjects, 5 males and 3 females, mean age 41.25 ± SD
14.64-years, with neurological diseases other than ALS (six with
sensory-motor peripheral neuropathy, one with probable multiple
sclerosis and one with cerebral vasculitis), with a comparable de-
gree of motor impairment as judged on the basis of the Appel score
(AS) functional rating scale at the time of the study and without
detectable CSF or plasma abnormalities at standard laboratory
analysis. The AS functional rating scale includes assessment of
swallowing, speech and respiratory function, and both strength and
function of upper and lower extremity musculature [5]. The diffi-
culty in getting CSF samples without laboratory abnormalities
justified the limited numbers of controls involved in our study. In
all ALS patients CSF standard laboratory examination did not show
alteration in cell counts, ors in total amount of protein, and no
oligoclonal bands were found.
Both the control and ALS groups habitually followed a dietary
regimen of Mediterranean type, this mainly being characterized
by high intake of vegetables, legumes, fruits, cereals and unsatu-
rated fats, particularly olive oil, and low to moderate intake of
dairy products. The smoking habits also did not differ between
the two groups, participating subjects mainly being non smokers.
None of the patients or controls was taking medications with
antioxidant properties. CSF samples, basically collected in an early
stage of disease (8.35 ± 12.7 months from the beginning of the
disease, range: 1–24), were taken by lumbar puncture. Approxi-
mately 6–8 ml of CSF were collected in polypropylene tubes for
diagnostic purposes. The samples were split into 1 ml aliquots
and stored at )80C prior to use. Eight ml of blood sample was
drawn from antecubital veins into Vacutainer tubes, centrifuged
to eliminate cells and other insoluble material, and the excess was
stored in 1 ml aliquots at )80C. The days elapsed between
sample collection and analysis defined the sample storage time
(28.78 ± 16.15 months).
All subjects gave their informed consent after the purpose of
study had been explained to them.
Methods
j Advanced oxidation protein products
Advanced oxidation protein products (AOPP) stable marker of
oxidative damage to proteins, were determined according to Witko-
Sarsat et al. [34]. Briefly: CSF or plasma were mixed with H2O,
acetic acid and potassium iodide. The absorbance was read spec-
trophotometrically at 340 nm and compared with a solution of
chloramine T dissolved in the same buffer. The data were expressed
as (mol/l of chloramine equivalents and related to CSF or plasma
total protein, albumin, and immunoglobulin concentration.
Ferric reducing ability
In order to measure non enzymatic anti-oxidant properties, ferric
reducing ability (FRA) was assessed according to Benzie et al. [9].
Briefly: the FRA reagent (sodium-acetate, tripiridiltriazyne in
hydrochloric acid and ferric chloride) pre-warmed to 37(C were
mixed with CSF or plasma; the absorbance was read after 3 min. at
593 nm. A calibration curve was established by substituting the
sample with a solution of iron sulphate in hydrochloric acid.
j 4-hydroxynonenal
4-HNE 4-hydroxynonenal (4-HNE) is a highly reactive but rela-
tively stable end product of oxidative degradation of arachidonic
acid and linoleic acid and its effect is concentration dependent.
Protein bound 4-Hydroxynonenal (HNE) was revealed in wes-
tern blots of CSF proteins in all the 8 patients and in controls by a
rabbit polyclonal antibody obtained by immunizing rats with key-
hole-limpet hemocyanin-4-HNE adducts. Immunoreactive bands
were revealed by enhanced chemiluminescence, and the intensity of
the bands was semi-quantitated by a Bio-Rad (Milano) [23].
Nitrites + nitrates assay
Nitrites and nitrates represent the stable end products of reaction
between nitric oxide and superoxide via peroxynitrite which then
decomposes rapidly to them [6, 23]. We determined the sum of
nitrites plus nitrates in 27 patients and in all controls, by the nitric
oxide quantitative kit (Active Motif, Firenze). Nitric oxide assay is
performed using a two-steps assay. The first step is the reduction of
nitrate into nitrite by nitrate reductase. In the final step, Griess
Reagent converts the nitrite into a purple-colored azo compound,
which is quantitated by spectrophotometer at A450 [16].
j Statistical analysis
In comparing the groups, we have assembled a Gaussian distribu-
tion of data, by using Student’s t test for unpaired data. Variance
analysis was performed by ANOVA, followed by the Neuman-Keuls
test for multiple comparisons.
Results
j Advanced oxidation protein products
CSF: AOPP were found to be significantly increased in
CSF of ALS patients compared with controls
(Mean ± SE = 13.2 ± 1.7 (mol/l, vs 0.75 ± 0.55 (mol/
l, p = 0.0039) [Fig. 1]. When the different clinical
forms of ALS were considered separately, patients
with the classical form (15.35 ± 2.47 (mol/l) or the
pseudopolyneuropathic form (18.02 ± 2.57 (mol/l)
still maintained significantly higher values of AOPP
(p < 0.001), while no difference was observed be-
tween patients with the bulbar form (1.1 ± 0.59 (mol/
l) and controls [Fig. 2].
Plasma: AOPP were found to be significantly in-
creased in plasma of ALS patients compared with
controls (Mean ± SE = 286.93 ± 110.12 (mol/l, vs
135.38 ± 77.83 (mol/l, p = 0.001) [Fig. 3]. No differ-
ence was found between AOPP in different clinical
forms of ALS.
No correlation between AOPP and total protein
content was found in CSF of ALS patients and con-
trols.
j Ferric reducing ability
CSF: FRA was found to be significantly decreased in
CSF of ALS patients compared with controls
(48.8 ± 2.2 (mol/l vs 61.3 ± 3.2 (mol/l, p = 0.003)
[Fig. 4], but no difference was found when comparing
the three clinical subsets of the disease with each
other.
Plasma: No difference was found between ALS
patients and controls or between the three clinical
subsets of the disease.
No correlation between values of either AOPP or
FRA and duration/severity of illness or sample storage
time was observed.
Protein-bound 4-hydroxynonenal
Most of the immunoreactive 4-HNE was found to be
associated with a 60 KDa band, probably corre-
sponding to albumin; however several additional
bands with higher molecular weight were also de-
tected. Immunoreactivity was stronger in ALS pa-
tients than in controls. However, when quantified, the
difference did not reach a statistical significance level
(data not shown).
Nitrites + nitrates assay
Comparable values of the sum [nitrite + nitrate] were
found in 27 examined ALS patients and in controls
(6.37 ± 0.72 (mol/l vs 6.71 ± 1.06 (mol/l, p = NS).
Further, the nitrites values of the two controls affected
by multiple sclerosis and vasculitis were similar to
those of the other six controls. No difference was
found between the different forms of ALS.
Fig. 1 values of AOPP in CSF of ALS patients and controls (difference
significant for p = 0.003)
Fig. 2 CSF values of AOPP in the clinical subsets of ALS (difference significant
for p < 0.001 in the comparison between controls or bulbar forms and classic
or progressive muscular atrophy)
Fig. 3 plasmatic AOPP values of ALS patients and controls (difference
significant for p = 0.001)
Fig. 4 values of FRA in CSF of ALS patients and controls (difference significant
for p = 0.003)
Discussion
Oxidative stress is considered one of the most chal-
lenging pathogenetic hypotheses in ALS. This possible
role is emphasized by reports that underline its
interconnection with other pathogenetic mechanisms
in ALS such as deranged neuron glutamate metabo-
lism [6] or protein aggregation [25]. Related to this,
the main result of this study is represented by, rather
than the finding of increased protein oxidation, a CSF-
confined involvement of non-enzymatic antioxidant
system in ALS patients. However, the different clinical
subsets of patients show different alteration in some of
the parameters analyzed. This suggests that oxidative
stress may not always be a disease determinant in ALS,
but rather variously involved in its different clinical
forms. This was observed for the advanced oxidation
protein products, while ferric reducing ability was
uniformly reduced in CSF of our patients.
Our study reveals that CSF and plasma protein
oxidation clearly occur in ALS patients. We found
that in ALS patients, significantly as compared to
controls, the total antioxidant capacity (FRA) was
decreased in CSF, while the content of oxidized pro-
teins (AOPP) was increased in both CSF and plasma.
In addition, when considering separately different
clinical forms of ALS, CSF increase of AOPP was
present in patients with the common form and the
progressive muscular atrophy form, but not in those
with the bulbar form.
Plasma AOPP are related to dityrosine, a marker of
oxidative damage to proteins [15], and are present in
plasma, in two distinct forms, 670 and 70 kDa in
molecular weight, corresponding respectively to
albumin aggregates and albumin monomeric form
[34]. Increase in plasma AOPP occurs in diabetes and
in renal failure. The AOPP values in our patients do
not appear to reflect CSF protein profile, therefore
suggesting that proteins other than albumins con-
tribute to this product. Other studies could be useful
to clarify that.
The FRA test measures the combined effect of the
non-enzymatic antioxidants, providing an index of
ability to prevent oxidative damage. In fact, biological
fluids contain several antioxidants, including not only
the well known antioxidant proteins, but also sub-
stances such as bilirubin, uric acid, albumin,
tocopherol and ascorbic acid whose modest reducing
potential is balanced by their elevated concentration
[13, 14]. In comparing CSF and plasma AOPP with
FRA results, while the increase of oxidised protein
level is observed in both CSF and plasma, the
reduction of antioxidant capacity assessed by FRA is
limited to the intrathecal compartment. This, result-
ing either from an excessive consumption of antiox-
idants or, more interesting, from an intrinsic
deficiency of factors concurring to FRA level, indi-
cates a wider exposure of central nervous system to
oxidative damage in ALS. According to the latter
possibility, the reports on genetic susceptibility of
ALS patients to some oxidative stress and mitochon-
drial function impairment have to be mentioned [18].
The fact that 4-HNE was found in all our ALS pa-
tients suggests that lipid peroxidation occurs in the
CNS of ALS patients. 4-HNE is a potential causative
molecule in neuronal damage. It modifies the affinity of
Na+-dependent glutamate transporters type 2 (EAAT2)
for glutamate, thus reducing EAAT2 capacity to re-
move this amino-acid from the synaptic wall [35]. An
increase of 4-HNE in the CSF of ALS patients [1, 2] has
already been shown. Absence of significant difference
compared with controls may be ascribed to the early
stage of the disease, as previously reported [28, 29].
Peroxynitrites derive by the reaction of nitric oxide
(NO) and superoxide anion radical. In the nucleus
peroxynitrite causes impaired ATP utilization, DNA
instability and cell death [36]. In addiction, nitric oxide
can be converted, in mitochondria, in peroxynitrite
which inactivates mitochondrial respiratory chain
proteins [24], Mn-SOD [17] and mitochondrial per-
meability transition pore (MPTP), leading to mito-
chondrial calcium efflux [20, 21], a pro-apoptosis step
[32]. Even if other studies [7] suggested that NO,
through peroxynitrite production,might be a causative
molecule of motor neuron death in ALS, our data seem
not to corroborate the role of nitrosylation in ALS.
Interestingly, when the different clinical presenta-
tions of ALS were compared with each other, CSF
oxidized protein level was elevated only in patients
with classic or pseudopolyneuropathic form of the
disease, while patients with bulbar form did not differ
from controls. The reason for this difference is not
clear. In ALS bulbar motor neurons are known to be
particularly susceptible to some cell damage mecha-
nism, partly related to oxidative stress as is the case of
the reported reduced expression of the antioxidant
enzyme Mn-SOD [31]. Therefore it is possible that
intrinsic differences between spinal and bulbar motor
neurons can explain their selective vulnerability to
various oxidative stress mechanisms.
In conclusion, in conjunction with the above-
mentioned evidence of the effects of reactive oxygen
species on protein oxidation, the present study
emphasizes the importance of a better understanding
of the precise role of oxidative stress in the patho-
genesis of ALS.
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